Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

TY - JOUR

T1 - Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

AU - Stevens, Wendy B. C.

AU - Los-de Vries, G. Tjitske

AU - Langois-Jacques, Carole

AU - Clear, Andrew J.

AU - Stathi, Phylicia

AU - Sander, Birgitta

AU - Rosenwald, Andreas

AU - Calaminici, Maria

AU - Hoster, Eva

AU - Hiddemann, Wolfgang

AU - Gaulard, Philippe

AU - Salles, Gilles

AU - Klapper, Wolfram

AU - Xerri, Luc

AU - Burton, Catherine

AU - Tooze, Reuben M.

AU - Smith, Alexandra G.

AU - Buske, Christian

AU - Scott, David W.

AU - Natkunam, Yasodha

AU - Advani, Ranjana

AU - Sehn, Laurie H.

AU - Raemaekers, John

AU - Gribben, John

AU - Lockmer, Sandra

AU - Kimby, Eva

AU - Kersten, Marie José

AU - Maucort-Boulch, Delphine

AU - Ylstra, Bauke

AU - van Dijk, Erik

AU - de Jong, Daphne

N1 - Funding Information: This study was supported by the Dutch Cancer Society grants KWF 2015-7925 and by unrestricted grants from: van Vlissingen Lymfoom Fonds, Genentech/Roche, GlaxoSmithKline, Pfizer Pharma, Teva, Pharmaceuticals/Cephalon, Millennium Pharmaceuticals Inc and Celgene. Haematological Malignancy Research Network is funded by Cancer Research UK, grant numbers 29685; and Blood Cancer UK, grant number 1503. GTLdV, DdJ, BY, and MJK received funding from the Dutch Cancer Society grants KWF 2015-7925. WBCS, EvD, CL-J, and DM-J were funded by unrestricted grants from: van Vlissingen Lymfoom Fonds, Genentech/Roche, GlaxoSmithKline, Pfizer Pharma, Teva, Pharmaceuticals/Cephalon, Millennium Pharmaceuticals Inc and Celgene. AGS was funded by Cancer Research UK and Blood Cancer UK. Funding Information: The Lunenburg Lymphoma Biomarker Consortium, MJK, BY, and DdJ designed the study; WBCS, GTL-dV, EvD, CLJ, AJC, PS performed experiments; WBCS, GTL-dV, EvD, CLJ, BS, AR, DMB, BY, and DdJ analyzed and interpreted the data; WBCS, GTL-dV, EvD, DMB, CLJ, BY, and DdJ wrote the manuscript; and all authors critically revised the manuscript and were involved in its editing and gave final approval of the submitted and published versions. The Lunenburg Lymphoma Biomarker Consortium (LLBC) is a collaboration of 9 international lymphoma research groups, each represented by one or more clinicians and hematopathologists and some also by one or more statisticians. Foundation of the LLBC was made possible with a grant from the van Vlissingen Lymphoma Foundation. EORTC Lymphoma group: Daphne de Jong, John Raemaekers. HOVON Lymphoma group: Daphne de Jong, Marie José Kersten. LYSA: Philippe Gaulard, Gilles Salles, Luc Xerri. Delphine Maucort-Boulch, Carole Langois-Jacques. British Columbia Cancer Agency: Laurie H. Sehn, David W. Scott. GLA: Andreas Rosenwald, Wolfram Klapper, Christian Buske, Wolfgang Hiddemann, Eva Hoster. Nordic lymphoma group: Birgitta Sander, Eva Kimby. Barts Cancer Institute: Maria Calaminici, John Gribben, Andrew J. Clear. Haematological Malignancy Research Network: Catherine Burton, Reuben M. Tooze, Alexandra G. Smith. Stanford Cancer Institute: Yasodha Natkunam, Ranjana Advani.

PY - 2023/4/5

Y1 - 2023/4/5

UR - https://www.scopus.com/pages/publications/85152207690

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85152207690&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/37038467

U2 - 10.1097/HS9.0000000000000863

DO - 10.1097/HS9.0000000000000863

M3 - Comment/Letter to the editor

C2 - 37038467

SN - 2572-9241

VL - 7

SP - E863

JO - HemaSphere

JF - HemaSphere

IS - 4

ER -